The CMA says that except with its prior written consent, Cooper and Coopervision UK shall not, during the specified period, take any action which might prejudice a reference of the transaction under section 22 of the Act or impede the taking of any action under the Act by the CMA which may be justified by the CMA’s decisions on such a reference, including any action which might:(a) lead to the integration of the Sauflon Business with the Cooper Business;(b) transfer the ownership or control of the Cooper Business or the Sauflon Business or any of its subsidiaries; or(c) otherwise impair the ability of the Sauflon Business or the Cooper Business to compete independently in any of the markets affected by the transaction.
ACO extends deadline to apply for paediatric eyecare course
The Australian College of Optometry (ACO) has extended the application deadline for its 2025 Advanced Certificate in Children’s Vision (ACCV)...